Marta Heras, Leticia Azcona, Octavio Arencibia, Lucas Minig, Lola Marti, Alicia Hernandez, Arantxa Lekuona, Isabel Niguez, Blanca Gil-Ibañez, Berta Diaz-Feijoo, Laia Ribot, Maria Nieves Cabezas, Marta Lamarca, Monica Bellon, Amira Alkourdi, Laura Cardenas, Ana Boldo, Joana Amengual, Mikel Gorostidi, Ignacio Zapardiel
{"title":"卵巢癌患者保留生育力治疗的肿瘤安全性：西班牙多中心研究。","authors":"Marta Heras, Leticia Azcona, Octavio Arencibia, Lucas Minig, Lola Marti, Alicia Hernandez, Arantxa Lekuona, Isabel Niguez, Blanca Gil-Ibañez, Berta Diaz-Feijoo, Laia Ribot, Maria Nieves Cabezas, Marta Lamarca, Monica Bellon, Amira Alkourdi, Laura Cardenas, Ana Boldo, Joana Amengual, Mikel Gorostidi, Ignacio Zapardiel","doi":"10.1002/ijgo.16026","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess the safety of fertility-sparing treatments for early-stage ovarian cancer in women younger than 40 years old.</p><p><strong>Methods: </strong>We performed a retrospective multicenter study including women aged 18-40 years diagnosed with early-stage (FIGO I-II) ovarian cancer in 55 Spanish hospitals, from January 2010 to December 2019. Benign and borderline tumors were excluded, as well as advanced stages (FIGO III-IV). All perioperative characteristics and follow-up data were collected and analyzed. Standard staging surgery (SSS) was compared with fertility-sparing surgery (FSS) in terms of oncological outcomes.</p><p><strong>Results: </strong>In all, 366 women were included; 327 (89.3%) were stage I. Among all patients, 216 (59%) underwent SSS and 150 (41%) FSS. Up to 208 (56.8%) patients did not have children, but only 12 (3.2%) had oocyte preservation before treatment. Patients in the FSS group compared with the SSS group showed a non-significant difference in recurrences (8% vs. 9.3%, respectively; P < 0.711) and deaths (1.3% vs. 4.8%, respectively; P = 0.211) during the follow-up. No significant differences were found between epithelial and non-epithelial ovarian cancer both in recurrences (7.1% vs. 8.8%, respectively; P = 0.771) and in deaths (1.4% vs. 1.3%, respectively; P = 1) among patients who underwent FSS.</p><p><strong>Conclusion: </strong>FSS seems a safe option for treatment of early-stage ovarian cancer in patients who want to preserve fertility, either for epithelial and non-epithelial histology.</p>","PeriodicalId":14164,"journal":{"name":"International Journal of Gynecology & Obstetrics","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Oncological safety of fertility preservation treatment in ovarian cancer: A Spanish multicenter study.\",\"authors\":\"Marta Heras, Leticia Azcona, Octavio Arencibia, Lucas Minig, Lola Marti, Alicia Hernandez, Arantxa Lekuona, Isabel Niguez, Blanca Gil-Ibañez, Berta Diaz-Feijoo, Laia Ribot, Maria Nieves Cabezas, Marta Lamarca, Monica Bellon, Amira Alkourdi, Laura Cardenas, Ana Boldo, Joana Amengual, Mikel Gorostidi, Ignacio Zapardiel\",\"doi\":\"10.1002/ijgo.16026\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To assess the safety of fertility-sparing treatments for early-stage ovarian cancer in women younger than 40 years old.</p><p><strong>Methods: </strong>We performed a retrospective multicenter study including women aged 18-40 years diagnosed with early-stage (FIGO I-II) ovarian cancer in 55 Spanish hospitals, from January 2010 to December 2019. Benign and borderline tumors were excluded, as well as advanced stages (FIGO III-IV). All perioperative characteristics and follow-up data were collected and analyzed. Standard staging surgery (SSS) was compared with fertility-sparing surgery (FSS) in terms of oncological outcomes.</p><p><strong>Results: </strong>In all, 366 women were included; 327 (89.3%) were stage I. Among all patients, 216 (59%) underwent SSS and 150 (41%) FSS. Up to 208 (56.8%) patients did not have children, but only 12 (3.2%) had oocyte preservation before treatment. Patients in the FSS group compared with the SSS group showed a non-significant difference in recurrences (8% vs. 9.3%, respectively; P < 0.711) and deaths (1.3% vs. 4.8%, respectively; P = 0.211) during the follow-up. No significant differences were found between epithelial and non-epithelial ovarian cancer both in recurrences (7.1% vs. 8.8%, respectively; P = 0.771) and in deaths (1.4% vs. 1.3%, respectively; P = 1) among patients who underwent FSS.</p><p><strong>Conclusion: </strong>FSS seems a safe option for treatment of early-stage ovarian cancer in patients who want to preserve fertility, either for epithelial and non-epithelial histology.</p>\",\"PeriodicalId\":14164,\"journal\":{\"name\":\"International Journal of Gynecology & Obstetrics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Gynecology & Obstetrics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ijgo.16026\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecology & Obstetrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ijgo.16026","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Oncological safety of fertility preservation treatment in ovarian cancer: A Spanish multicenter study.
Objective: To assess the safety of fertility-sparing treatments for early-stage ovarian cancer in women younger than 40 years old.
Methods: We performed a retrospective multicenter study including women aged 18-40 years diagnosed with early-stage (FIGO I-II) ovarian cancer in 55 Spanish hospitals, from January 2010 to December 2019. Benign and borderline tumors were excluded, as well as advanced stages (FIGO III-IV). All perioperative characteristics and follow-up data were collected and analyzed. Standard staging surgery (SSS) was compared with fertility-sparing surgery (FSS) in terms of oncological outcomes.
Results: In all, 366 women were included; 327 (89.3%) were stage I. Among all patients, 216 (59%) underwent SSS and 150 (41%) FSS. Up to 208 (56.8%) patients did not have children, but only 12 (3.2%) had oocyte preservation before treatment. Patients in the FSS group compared with the SSS group showed a non-significant difference in recurrences (8% vs. 9.3%, respectively; P < 0.711) and deaths (1.3% vs. 4.8%, respectively; P = 0.211) during the follow-up. No significant differences were found between epithelial and non-epithelial ovarian cancer both in recurrences (7.1% vs. 8.8%, respectively; P = 0.771) and in deaths (1.4% vs. 1.3%, respectively; P = 1) among patients who underwent FSS.
Conclusion: FSS seems a safe option for treatment of early-stage ovarian cancer in patients who want to preserve fertility, either for epithelial and non-epithelial histology.
期刊介绍：
The International Journal of Gynecology & Obstetrics publishes articles on all aspects of basic and clinical research in the fields of obstetrics and gynecology and related subjects, with emphasis on matters of worldwide interest.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
